about
Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvantDevelopment of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical SynthesisDelta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza VaccineControlling the HIV/AIDS epidemic: current status and global challengesThe polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions.Multifaceted Applications of Chitosan in Cancer Drug Delivery and Therapy.The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro.Femtosecond laser-induced cell-cell surgical attachment.Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.Technologies for enhanced efficacy of DNA vaccines.Potential of nanoparticles for allergen-specific immunotherapy - use of silica nanoparticles as vaccination platform.Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsThe future of human DNA vaccinesApplications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.A polysaccharide isolated from Agaricus blazei Murill (ABP-AW1) as a potential Th1 immunity-stimulating adjuvant.Novel adjuvants & delivery vehicles for vaccines development: a road aheadMechanisms of Cholera Toxin in the Modulation of TH17 Responses.Chlamydia vaccines: recent developments and the role of adjuvants in future formulations.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.Carbohydrate-based vaccine adjuvants - discovery and development.Recent advances in vaccine delivery.Implications of plant glycans in the development of innovative vaccines.An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators.Chemistry and biology of oligovalent β-(1→2)-linked oligomannosides: new insights into carbohydrate-based adjuvants in immunotherapy.Scientific Opinion on the evaluation of the substances currently on the list in the Annex to Commission Directive 96/3/EC as acceptable previous cargoes for edible fats and oils - Part I of IIIScientific Opinion on the evaluation of the substances currently on the list in the annex to Commission Directive 96/3/EC as acceptable previous cargoes for edible fats and oils - Part II of IIIScientific Opinion on the evaluation of the substances currently on the list in the annex to Commission Directive 96/3/EC as acceptable previous cargoes for edible fats and oils - Part III of IIITailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems.C-Type Lectin Receptor (CLR)-Fc Fusion Proteins As Tools to Screen for Novel CLR/Bacteria Interactions: An Exemplary Study on Preselected Campylobacter jejuni Isolates.Prospects on the Use of sp. to Develop Oral Vaccines
P2860
Q28384323-8ED21064-30F7-4A7D-8D06-CD4924E96CCBQ28829361-2B910FF3-AA24-4CC2-940A-7A7C13B520EFQ30376743-C9D2171B-7D13-4878-8905-918D987725BDQ30420558-D8D32DF5-7867-4E7C-A307-46041CC438FEQ30655287-493291D5-2772-43FB-93C3-8240B5C9E8BEQ33612179-62326419-242D-4A98-B241-738C05165F5DQ33710401-2E23336C-A13A-4CE5-A299-43A593996404Q35097042-8A07FF74-B7EE-4D29-A744-A80B8121CAFEQ35111000-4C1E0DB9-7E34-4B32-9EAD-7D04D140439BQ35802958-3415841D-D480-4638-A01D-161220C9A52FQ36056484-E8C9406D-6F2B-44A8-94E3-12AD325270CDQ36191001-D6090228-C7FE-4CAB-9276-66473B89FDCFQ36438236-A87491F5-2622-42B3-8E98-DC5DD8D894EAQ36591050-5966389D-D912-4464-918A-322507816DD0Q37229386-4100D625-93C7-4579-88EF-0C6F3E9C45DDQ37592383-BBDF05AB-CD03-48FD-8109-1A99CEDAE333Q37641941-83E52FEB-4006-43F8-996D-7C4F09330B13Q37849913-849366C1-F1F5-4189-84A5-AC01A50F6EAAQ38264288-DE974459-770C-40E8-8937-9D7DCDF2F852Q38587300-93BD1CCC-A59B-4B83-931E-165FC28C02AEQ38669255-642A814C-7F90-472E-AA54-54A632A40191Q38738762-713D067D-C6AF-4900-8BFD-4F74F639ADB4Q39174792-282D0F0B-F276-408D-9E19-334A8BD6145EQ43635984-8D31D8A9-2D13-4047-BCD9-BAEB13C78EEDQ47150985-56DF0F0D-282E-411D-831D-80AB69336F6AQ47151803-10E21A48-F273-43C1-97A8-2DD58591787BQ47152691-FF575A40-3580-42AC-9B7F-5D120501811DQ47690085-6D59BE1B-45D7-4B7F-97C1-2DC7BD8B8AE5Q50417216-62A1A2F3-AF23-4928-9CFB-BF2AB784AC90Q58556430-F9A3B6F5-5D0D-4EF6-8EB7-A4D779CD91DC
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Carbohydrate-based immune adjuvants.
@ast
Carbohydrate-based immune adjuvants.
@en
type
label
Carbohydrate-based immune adjuvants.
@ast
Carbohydrate-based immune adjuvants.
@en
prefLabel
Carbohydrate-based immune adjuvants.
@ast
Carbohydrate-based immune adjuvants.
@en
P2860
P356
P1476
Carbohydrate-based immune adjuvants.
@en
P2093
Peter D Cooper
P2860
P304
P356
10.1586/ERV.11.30
P577
2011-04-01T00:00:00Z